- Home
- MDXH vs SRZN Comparison
MDXH vs SRZN Comparison
Compare MDXH & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- SRZN
- Stock Information
- Founded
- MDXH 2003
- SRZN 2015
- Country
- MDXH Belgium
- SRZN United States
- Employees
- MDXH N/A
- SRZN N/A
- Industry
- MDXH
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- MDXH
- SRZN Health Care
- Exchange
- MDXH Nasdaq
- SRZN Nasdaq
- Market Cap
- MDXH 73.3M
- SRZN 82.8M
- IPO Year
- MDXH 2021
- SRZN N/A
- Fundamental
- Price
- MDXH $1.76
- SRZN $10.03
- Analyst Decision
- MDXH Buy
- SRZN Strong Buy
- Analyst Count
- MDXH 1
- SRZN 2
- Target Price
- MDXH $6.00
- SRZN $38.50
- AVG Volume (30 Days)
- MDXH 55.7K
- SRZN 10.7K
- Earning Date
- MDXH 05-05-2025
- SRZN 05-07-2025
- Dividend Yield
- MDXH N/A
- SRZN N/A
- EPS Growth
- MDXH N/A
- SRZN N/A
- EPS
- MDXH N/A
- SRZN N/A
- Revenue
- MDXH $90,049,000.00
- SRZN $10,655,000.00
- Revenue This Year
- MDXH $23.38
- SRZN N/A
- Revenue Next Year
- MDXH $16.84
- SRZN N/A
- P/E Ratio
- MDXH N/A
- SRZN N/A
- Revenue Growth
- MDXH 28.29
- SRZN N/A
- 52 Week Low
- MDXH $1.35
- SRZN $6.00
- 52 Week High
- MDXH $3.50
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- MDXH 66.56
- SRZN 46.52
- Support Level
- MDXH $1.51
- SRZN $9.57
- Resistance Level
- MDXH $1.64
- SRZN $10.58
- Average True Range (ATR)
- MDXH 0.08
- SRZN 0.59
- MACD
- MDXH 0.04
- SRZN 0.07
- Stochastic Oscillator
- MDXH 93.02
- SRZN 68.59
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).